165 research outputs found
Advanced Shipboard Communications Demonstrations with ACTS
For ships at sea, satellites provide the only option for high data rate (HDR), long haul communications. Furthermore the demand for HDR satellite communications (SATCOM) for military and commercial ships, and other offshore platforms is increasing. Presently the bulk of this maritime HDR SATCOM connectivity is provided via C-band and X-band. However, the shipboard antenna sizes required to achieve a data rate of, say T1 (1.544 Mbps) with present C-/X-band SATCOM systems range from seven to ten feet in diameter. This limits the classes of ships to which HDR services can be provided to those which are large enough to accommodate the massive antennas. With its high powered K/Ka-band spot beams, the National Aeronautics and Space Administration\u27s (NASA) Advanced Communications Technology Satellite (ACTS) was able to provide T1 and higher rate services to ships at sea using much smaller shipboard antennas. This paper discusses three shipboard HDR SATCOM demonstrations that were conducted with ACTS between 1996 and 1998.
The first demonstration involved a 2 Mbps link provided to the seismic survey ship M/V Geco Diamond equipped with a 16-inch wide, 4.5-inch tall, mechanically steered slotted waveguide array antenna developed by the Jet Propulsion Laboratory. In this February 1996 demonstration ACTS allowed supercomputers ashore to process Geco Diamond\u27s voluminous oceanographic seismic data in near real time. This capability allowed the ship to adjust its search parameters on a daily basis based on feedback from the processed data, thereby greatly increasing survey efficiency.
The second demonstration was conducted on the US Navy cruiser USS Princeton (CG 59) with the same antenna used on Geco Diamond. Princeton conducted a six-month (January-July 1997) Western Hemisphere solo deployment during which time T1 connectivity via ACTS provided the ship with a range of valuable tools for operational, administrative and quality-of-life tasks. In one instance, video teleconferencing (VTC) via ACTS allowed the ship to provide life-saving emergency medical aid, assisted by specialists ashore, to a fellow mariner - the Master of a Greek cargo ship.
The third demonstration set what is believed to be the all-time SATCOM data rate record to a ship at sea, 45 Mbps in October 1998. This Lake Michigan (Chicago area) demonstration employed one of ACTS\u27 fixed beams and involved the smallest of the three vessels, the 45-foot Bayliner M/V Entropy equipped with a modified commercial-off-the-shelf one-meter antenna. A variety of multi-media services were provided to Entropy through a stressing range of sea states. These three demonstrations provided a preview of the capabilities that could be provided to future mariners on a more routine basis when K/Ka-band SATCOM systems are widely deployed
Rapid and efficient stable gene transfer to mesenchymal stromal cells using a modified foamy virus vector
Mesenchymal stromal cells (MSCs) hold great promise for regenerative medicine. Stable ex vivo gene transfer to MSCs could improve the outcome and scope of MSC therapy, but current vectors require multiple rounds of transduction, involve genotoxic viral promoters and/or the addition of cytotoxic cationic polymers in order to achieve efficient transduction. We describe a self-inactivating foamy virus vector (FVV), incorporating the simian macaque foamy virus envelope and using physiological promoters, which efficiently transduces murine MSCs (mMSCs) in a single-round. High and sustained expression of the transgene, whether GFP or the lysosomal enzyme, arylsulphatase A (ARSA), was achieved. Defining MSC characteristics (surface marker expression and differentiation potential), as well as long-term engraftment and distribution in the murine brain following intracerebroventricular delivery, are unaffected by FVV transduction. Similarly, greater than 95% of human MSCs (hMSCs) were stably transduced using the same vector, facilitating human application. This work describes the best stable gene transfer vector available for mMSCs and hMSCs
Recurrent encephalopathy: NAGS (N-Acetylglutamate Synthase) deficiency in adults
N-acetyl-glutamate synthase (NAGS) deficiency is a rare autosomal recessive urea cycle disorder (UCD) that uncommonly presents in adulthood. Adult presentations of UCDs include; confusional episodes, neuropsychiatric symptoms and encephalopathy. To date, there have been no detailed neurological descriptions of an adult onset presentation of NAGS deficiency. In this review we examine the clinical presentation and management of UCDs with an emphasis on NAGS deficiency. An illustrative case is provided. Plasma ammonia levels should be measured in all adult patients with unexplained encephalopathy, as treatment can be potentially life-saving. Availability of N-carbamylglutamate (NCG; carglumic acid) has made protein restriction largely unnecessary in treatment regimens currently employed. Genetic counselling remains an essential component of management of NAGS
The expanding phenotype of MELAS caused by the m.3291T \u3e C mutation in the MT-TL1 gene
Crown Copyright © 2016 Published by Elsevier Inc. m.3291T \u3e C mutation in the MT-TL1 gene has been infrequently encountered in association with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS), however remains poorly characterized from a clinical perspective. In the following report we describe in detail the phenotypic features, long term follow up (\u3e 7 years) and management in a Caucasian family with MELAS due to the m.3291T \u3e C mutation and review the literature on m.3291T \u3e C mutation. The clinical phenotype in the proposita included overlapping features of MELAS, MERRF (Myoclonic epilepsy and ragged-red fiber syndrome), MNGIE (Mitochondrial neurogastrointestinal encephalopathy), KSS (Kearns-Sayre Syndrome) and CPEO (Chronic progressive external ophthalmoplegia)
Response to: Letter to the Editor Regarding: The Expanding Phenotype of MELAS Caused by the m.3291 T \u3e C tRNA Mutation E Kelland, C. A. Rupar, Asuri N. Prasad, K. Y. Tay, A. Downie and C. Prasad (1) by Josef Finsterer, MD, PhD [1], Sinda Zarrouk-Mahjoub, PhD [2] [1] Krankenanstalt Rudolfstiftung, Vienna [2] Genomics Platform, Pasteur Institute of Tunis, Tunisia
MELAS: A multigenerational impact of the MTTL1 A3243G MELAS mutation
Background: the maternally inherited MTTL1 A3243G mutation in the mitochondrial genome causes MelaS (Mitochondrial encephalopathy lactic acidosis with Stroke-like episodes), a condition that is multisystemic but affects primarily the nervous system. Significant intra-familial variation in phenotype and severity of disease is well recognized. Methods: retrospective and ongoing study of an extended family carrying the MTTL1 A3243G mutation with multiple symptomatic individuals. tissue heteroplasmy is reviewed based on the clinical presentations, imaging studies, laboratory findings in affected individuals and pathological material obtained at autopsy in two of the family members. Results: there were seven affected individuals out of thirteen members in this three generation family who each carried the MTTL1 A3243G mutation. the clinical presentations were varied with symptoms ranging from hearing loss, migraines, dementia, seizures, diabetes, visual manifestations, and stroke like episodes. three of the family members are deceased from MelaS or to complications related to MelaS. Conclusions: the results of the clinical, pathological and radiological findings in this family provide strong support to the current concepts of maternal inheritance, tissue heteroplasmy and molecular pathogenesis in MelaS. neurologists (both adult and paediatric) are the most likely to encounter patients with MelaS in their practice. genetic counselling is complex in view of maternal inheritance and heteroplasmy. newer therapeutic options such as arginine are being used for acute and preventative management of stroke like episodes. © 2014 Canadian Journal of neurologiCal sciences inc
Simulated diabetic ketoacidosis therapy in vitro elicits brain cell swelling via sodium-hydrogen exchange and anion transport.
A common complication of type 1 diabetes mellitus is diabetic ketoacidosis (DKA), a state of severe insulin deficiency. A potentially harmful consequence of DKA therapy in children is cerebral edema (DKA-CE); however, the mechanisms of therapy-induced DKA-CE are unknown. Our aims were to identify the DKA treatment factors and membrane mechanisms that might contribute specifically to brain cell swelling. To this end, DKA was induced in juvenile mice with the administration of the pancreatic toxins streptozocin and alloxan. Brain slices were prepared and exposed to DKA-like conditions in vitro. Cell volume changes were imaged in response to simulated DKA therapy. Our experiments showed that cell swelling was elicited with isolated DKA treatment components, including alkalinization, insulin/alkalinization, and rapid reductions in osmolality. Methyl-isobutyl-amiloride, a nonselective inhibitor of sodium-hydrogen exchangers (NHEs), reduced cell swelling in brain slices elicited with simulated DKA therapy (in vitro) and decreased brain water content in juvenile DKA mice administered insulin and rehydration therapy (in vivo). Specific pharmacological inhibition of the NHE1 isoform with cariporide also inhibited cell swelling, but only in the presence of the anion transport (AT) inhibitor 4,4\u27-diisothiocyanatostilbene-2,2\u27-disulphonic acid. DKA did not alter brain NHE1 isoform expression, suggesting that the cell swelling attributed to the NHE1 was activity dependent. In conclusion, our data raise the possibility that brain cell swelling can be elicited by DKA treatment factors and that it is mediated by NHEs and/or coactivation of NHE1 and AT
Transcriptional Profiling of Endocrine Cerebro-Osteodysplasia Using Microarray and Next-Generation Sequencing
BACKGROUND: Transcriptome profiling of patterns of RNA expression is a powerful approach to identify networks of genes that play a role in disease. To date, most mRNA profiling of tissues has been accomplished using microarrays, but next-generation sequencing can offer a richer and more comprehensive picture. METHODOLOGY/PRINCIPAL FINDINGS: ECO is a rare multi-system developmental disorder caused by a homozygous mutation in ICK encoding intestinal cell kinase. We performed gene expression profiling using both cDNA microarrays and next-generation mRNA sequencing (mRNA-seq) of skin fibroblasts from ECO-affected subjects. We then validated a subset of differentially expressed transcripts identified by each method using quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Finally, we used gene ontology (GO) to identify critical pathways and processes that were abnormal according to each technical platform. Methodologically, mRNA-seq identifies a much larger number of differentially expressed genes with much better correlation to qRT-PCR results than the microarray (r² = 0.794 and 0.137, respectively). Biologically, cDNA microarray identified functional pathways focused on anatomical structure and development, while the mRNA-seq platform identified a higher proportion of genes involved in cell division and DNA replication pathways. CONCLUSIONS/SIGNIFICANCE: Transcriptome profiling with mRNA-seq had greater sensitivity, range and accuracy than the microarray. The two platforms generated different but complementary hypotheses for further evaluation
Autologous, lentivirus-modified, T-rapa cell “micropharmacies” for lysosomal storage disorders
T cells are the current choice for many cell therapy applications. They are relatively easy to access, expand in culture, and genetically modify. Rapamycin-conditioning ex vivo reprograms T cells, increasing their memory properties and capacity for survival, while reducing inflammatory potential and the amount of preparative conditioning required for engraftment. Rapamycin-conditioned T cells have been tested in patients and deemed to be safe to administer in numerous settings, with reduced occurrence of infusion-related adverse events. We demonstrate that ex vivo lentivirus-modified, rapamycin-conditioned CD4+ T cells can also act as next-generation cellular delivery vehicles—that is, “micropharmacies”—to disseminate corrective enzymes for multiple lysosomal storage disorders. We evaluated the therapeutic potential of this treatment platform for Fabry, Gaucher, Farber, and Pompe diseases in vitro and in vivo. For example, such micropharmacies expressing α-galactosidase A for treatment of Fabry disease were transplanted in mice where they provided functional enzyme in key affected tissues such as kidney and heart, facilitating clearance of pathogenic substrate after a single administration
- …